AGNC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AGNC Investment Corp is not a strong buy for a beginner, long-term investor at this moment. While the stock offers an attractive dividend yield of 12.8% and has shown strong financial performance in the latest quarter, declining earnings, potential dividend cuts, insider selling, and mixed analyst sentiment suggest caution. Additionally, technical indicators do not signal a clear buying opportunity, and there are no strong proprietary trading signals to support an immediate purchase.
The MACD histogram is negative and contracting (-0.075), indicating bearish momentum. RSI is neutral at 45.393, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 11.456, with support at 11.192 and resistance at 11.72. Overall, technical indicators suggest a neutral to slightly bearish trend.
Attractive forward dividend yield of 12.8%, appealing for passive income investors.
Strong financial performance in Q4 2025, with revenue up 93.63% YoY and net income up 955.81% YoY.
Analysts see potential tailwinds from expected Fed rate cuts in 2026, which could benefit agency MBS REIT stocks.
Insider selling has increased significantly (4402.22% over the last month).
Analysts have mixed ratings, with recent downgrades citing valuation concerns and balanced risk-reward profiles.
Declining earnings and potential dividend cuts due to rising financing costs.
No recent proprietary trading signals or congress trading data to support a bullish stance.
In Q4 2025, AGNC reported impressive financial growth: Revenue increased by 93.63% YoY to $1.733 billion, Net Income surged 955.81% YoY to $908 million, EPS rose 730% YoY to $0.83, and Gross Margin improved by 233.59% YoY to 57.41%. These figures highlight strong operational performance during the quarter.
Analyst sentiment is mixed. RBC Capital and Wells Fargo raised price targets to $13 and $12, respectively, with Outperform and Overweight ratings. However, Keefe Bruyette and JonesResearch downgraded the stock, citing valuation concerns and a balanced risk-reward profile. The current price target range is $10-$13, with a median target of $12.
